FDA Approves Pancreatic Enzyme Products to Aid Digestion

02 Mar 2012 --- Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Mar 2 2012 --- Two new pancreatic enzyme products used to help aid food digestion, Ultresa (pancrelipase) and Viokace (pancrelipase), were approved by the U.S. Food and Drug Administration.

Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Viokace, in combination with a proton pump inhibitor, is used to treat adults who cannot digest food normally. Adults with chronic pancreatitis, a continuing, chronic inflammatory process of the pancreas, or those who have had some or all of their pancreases removed (pancreatectomy) may not digest food normally because they lack needed enzymes or because their enzymes are not released into the bowel (intestine). Viokace’s safety and efficacy in children has not been established.

“The approvals of Ultresa and Viokace, along with the other approved pancreatic enzyme products, allow health care providers to prescribe the product that is most appropriate for the estimated 200,000 patients in the United States who have pancreatic insufficiency,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in FDA’s Center for Drug Evaluation and Research.

Ultresa and Viokace are the fourth and fifth pancreatic enzyme products approved by FDA. Other FDA-approved pancreatic enzyme products include Creon (2009), Zenpep (2009) and Pancreaze (2010). Approved pancreatic enzyme products meet FDA standards for safety, efficacy and product quality.

Unapproved pancreatic enzyme products had been available for many years. FDA established a date of April 28, 2010 for the makers of pancreatic enzyme products to stop manufacturing and distributing unapproved products.

Ultresa and Viokace are marketed by Bridgewater, N.J.-based Aptalis Pharma U.S. Inc.
 

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Nutrition & Health News

Dosage questions: Green tea supplements may pose health risks, EFSA warns

19 Apr 2018 --- When taken as food supplements, green tea catechin doses at or above 800mg/day may pose health concerns, according to the European Food Safety Authority (EFSA), which assessed the safety of green tea catechins from dietary sources, following concerns regarding their possible harmful effects on the liver. Catechins from green tea infusions and similar drinks are generally safe, the authority found, but certain supplements may be best avoided.

Nutrition & Health News

Probiotic peanut allergy treatment: Chr. Hansen enters new partnership

18 Apr 2018 --- Probiotic strain, LGG, can potentially play a part in peanut allergy treatment. Prota Therapeutics, developer of oral immunotherapies to treat food allergies, has partnered with Chr. Hansen, Danish food ingredients producer, to assess LGG in a clinical trial to develop a treatment for the allergy. Chr. Hansen tells NutritionInsight that the partnership is in effect as from today, and strengthens the position of Chr. Hansen in a market expected to grow to €10billion by 2025.

Nutrition & Health News

Beneo's functional carbohydrate gains Argentinian approval 

16 Apr 2018 --- Beneo’s Palatinose functional carbohydrate (isomaltulose) has been approved for use in all food and drink categories in Argentina, the company has reported. Palatinose is naturally-sourced and delivers full carbohydrate energy (4kcal/g) in a more balanced way, due to a slower and more sustained uptake. This results in higher fat oxidation and a low glycemic effect which can aid diet-related problems such as obesity and diabetes.

Nutrition & Health News

US FDA moves to ban bulk sale of concentrated caffeine products to consumers 

16 April 2018 --- The US Food and Drug Administration (FDA) has issued guidance declaring that dietary supplements containing pure or highly concentrated caffeine, in powder or liquid forms, are unlawful when sold in bulk quantities directly to consumers. The agency notes that it is prepared to take immediate steps to begin removing such “dangerous bulk products.”

Nutrition & Health News

US FDA's voluntary sodium target implementation could save US$40bn, study shows

11 Apr 2018 --- A study has revealed the potential health and economic benefits that could be reaped if the voluntary sodium reduction goals from the US Food and Drug Administration (FDA) would be implemented. The study, published in PLOS Medicine, found that more than US$40 billion could be saved over 20 years if the goals were indeed put into practice. The goals, released in 2016, set limits on how much salt should be in certain foods from food companies and restaurants.

More Articles
URL : http://www.nutritioninsight.com:80/news/FDA-Approves-Pancreatic-Enzyme-Products-to-Aid-Digestion.html